

Supplementary table 3. Acclidinium treatment differences in SGRQ total score and the percentage of patients achieving a clinically significant improvement in SGRQ total score (≥ 4 points) at week 24 in patients who experienced an EXACT-unreported event, an HCRU event and no exacerbation in the first 12 weeks (ITT population)

Treatment differences at week 24 aclidinium 400 µg versus aclidinium 200 µg	
SGRQ total score	
EXACT-unreported event (95% CI)	-2.54 (-7.82–2.74) p=0.344
HCRU event (95% CI)	-0.54 (-8.98–7.91) p=0.900
No exacerbation (95% CI)	-0.20 (-2.75–2.34) p=0.875
Aclidinium 400 µg versus aclidinium 200 µg	
SGRQ responders at week 24	
EXACT-unreported event, %	50.0% vs 46.2% Odds ratio p=0.643
HCRU event, %	50.0% vs 47.8% Odds ratio p=0.839
No exacerbation, %	59.9% vs 59.5% Odds ratio p=0.826

HCRU: aclidinium 200 µg BID n=23, aclidinium 400 µg BID n=26.

EXACT-unreported: aclidinium 200 µg BID n=52, aclidinium 400 µg BID n=46.

No exacerbation: aclidinium 200 µg BID n=200, aclidinium 400 µg BID n=197.

BID, twice daily; CI, confidence interval; EXACT, EXAcerbations of Chronic obstructive pulmonary disease Tool; HCRU, healthcare resource utilisation; ITT, intent-to-treat; SGRQ: St George's Respiratory Questionnaire.